Pepper AN, Assaad A, Blaiss M, Brown E, Chinthrajah S, Ciaccio C, et al. Consensus report from the food allergy research & education (FARE) 2019 oral immunotherapy for food allergy summit. J Allergy Clin Immunol. 2020;146(2):244–9.
Bégin P, Chan ES, Kim H, Wagner M, Cellier MS, Favron-Godbout C, et al. CSACI guidelines for the ethical, evidence-based and patient-oriented clinical practice of oral immunotherapy in IgE-mediated food allergy. Allergy Asthma Clin Immunol. 2020;18(16):20.
Levy MB, Elizur A, Goldberg MR, Nachshon L, Katz Y. Clinical predictors for favorable outcomes in an oral immunotherapy program for IgE-mediated cow’s milk allergy. Ann Allergy Asthma Immunol. 2014;112(1):58-63.e1.
Article CAS PubMed Google Scholar
Kansen HM, Le T-M, Knulst AC, Gorissen DMW, van der Ent CK, Meijer Y, et al. Three-year follow-up after peanut food challenges: Accidental reactions in allergic children and introduction failure in tolerant children. J Allergy Clin Immunol. 2020;145(2):705-707.e7.
Hourihane J, Beyer K, Abbas A, Fernández-Rivas M, Turner PJ, Blumchen K, et al. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. Lancet Child Adolesc Health. 2020;4(10):728–39.
Chu DK, Wood RA, French S, Fiocchi A, Jordana M, Waserman S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet. 2019;393(10187):2222–32.
Article CAS PubMed Google Scholar
Kulmala P, Pelkonen AS, Kuitunen M, Paassilta M, Remes S, Schultz R, et al. Wheat oral immunotherapy was moderately successful but was associated with very frequent adverse events in children aged 6–18 years. Acta Paediatr. 2018;107(5):861–70.
Article CAS PubMed Google Scholar
Zhu R, Robertson K, Protudjer JLP, Macikunas A, Kim R, Jeimy S, et al. Impact of age on adherence and efficacy of peanut oral-immunotherapy using a standardized protocol. Pediatr Allergy Immunol. 2021;32(4):783–6.
Soller L, Abrams EM, Carr S, Kapur S, Rex GA, Leo S, et al. First real-world effectiveness analysis of preschool peanut oral immunotherapy. J Allergy Clin Immunol Pract. 2021;9(3):1349-1356.e1.
Article CAS PubMed Google Scholar
Bird JA, Spergel JM, Jones SM, Rachid R, et al. Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial. J Allergy Clin Immunol Pract. 2018;6(2):476-485.e3.
Kauppila TK, Paassilta M, Kukkonen AK, Kuitunen M, Pelkonen AS, Makela MJ. Outcome of oral immunotherapy for persistent cow’s milk allergy from 11 years of experience in Finland. Pediatr Allergy Immunol. 2019;30(3):356–62.
Nachshon L, Goldberg MR, Levy MB, Appel MY, Epstein-Rigbi N, Lidholm J, et al. Efficacy and safety of sesame oral immunotherapy-a real-world, single-center study. J Allergy Clin Immunol Pract. 2019;7(8):2775-2781.e2.
Wasserman RL, Hague AR, Pence DM, Sugerman RW, Silvers SK, Rolen JG, et al. Real-world experience with peanut oral immunotherapy: lessons learned from 270 patients. J Allergy Clin Immunol Pract. 2019;7(2):418-426.e4.
PALISADE Group of Clinical Investigators, Vickery BP, Vereda A, Casale TB, Beyer K, du Toit G, et al. AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379(21):1991–2001.
Escudero C, Rodríguez Del Río P, Sánchez-García S, Pérez-Rangel I, Pérez-Farinós N, García-Fernández C, et al. Early sustained unresponsiveness after short-course egg oral immunotherapy: a randomized controlled study in egg-allergic children. Clin Exp Allergy. 2015;45(12):1833–43.
Article CAS PubMed Google Scholar
Reier-Nilsen T, Michelsen MM, Lødrup Carlsen KC, Carlsen K-H, Mowinckel P, Nygaard UC, et al. Feasibility of desensitizing children highly allergic to peanut by high-dose oral immunotherapy. Allergy. 2019;74(2):337–48.
Article CAS PubMed Google Scholar
Mori F, Cianferoni A, Brambilla A, Barni S, Sarti L, Pucci N, et al. Side effects and their impact on the success of milk oral immunotherapy (OIT) in children. Int J Immunopathol Pharmacol. 2017;30(2):182–7.
Article CAS PubMed PubMed Central Google Scholar
Virkud YV, Burks AW, Steele PH, Edwards LJ, Berglund JP, Jones SM, et al. Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy. J Allergy Clin Immunol. 2017;139(3):882-888.e5.
Afinogenova Y, Rubin TN, Patel SD, Powell RL, Gilo JM, Denno MN, et al. Community private practice clinical experience with peanut oral immunotherapy. J Allergy Clin Immunol Pract. 2020;8(8):2727–35.
Trevisonno J, Venter C, Pickett-Nairne K, Bégin P, Cameron SB, Chan ES, et al. Food aversion and anxiety represent primary patient barriers to food oral immunotherapy. J Allergy Clin Immunol Pract. 2024. https://doi.org/10.1016/j.jaip.2024.03.014.
Nachshon L, Goldberg MR, Katz Y, Levy MB, Elizur A. Long-term outcome of peanut oral immunotherapy-Real-life experience. Pediatr Allergy Immunol. 2018;29(5):519–26.
Dantzer J, Dunlop J, Psoter KJ, Keet C, Wood R. Efficacy and safety of baked milk oral immunotherapy in children with severe milk allergy: A randomized, double-blind, placebo-controlled phase 2 trial. J Allergy Clin Immunol. 2022;149(4):1383-1391.e17.
Article CAS PubMed Google Scholar
Haj Yahia S, Machnes-Maayan D, Frizinsky S, Maoz-Segal R, Offenganden I, Kenett RS, et al. Oral immunotherapy for children with a high-threshold peanut allergy. Ann Allergy Asthma Immunol. 2022;129(3):347–53.
Mack DP, Greenhawt M, Turner PJ, Wasserman RL, Hanna MA, Shaker M, et al. Information needs of patients considering oral immunotherapy for food allergy. Clin Exp Allergy. 2022;52(12):1391–402.
Howe LC, Leibowitz KA, Perry MA, Bitler JM, Block W, Kaptchuk TJ, et al. Changing patient mindsets about non-life-threatening symptoms during oral immunotherapy: a randomized clinical trial. J Allergy Clin Immunol Pract. 2019;7(5):1550–9.
Article PubMed PubMed Central Google Scholar
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101.
Jones SM, Kim EH, Nadeau KC, Nowak-Wegrzyn A, Wood RA, Sampson HA, et al. Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. Lancet. 2022;399(10322):359–71.
Article CAS PubMed Google Scholar
Mack DP, Dribin TE, Turner PJ, Wasserman RL, Hanna MA, Shaker M, et al. Preparing patients for oral immunotherapy (PPOINT): international Delphi consensus for procedural preparation and consent. J Allergy Clin Immunol. 2024;153:6.
Polloni L, Muraro A. Anxiety and food allergy: A review of the last two decades. Clin Exp Allergy. 2020;50(4):420–41.
Protudjer JLP, Golding M, Salisbury MR, Abrams EM, Roos LE. High anxiety and health-related quality of life in families with children with food allergy during coronavirus disease 2019. Ann Allergy Asthma Immunol. 2021;126(1):83-88.e1.
Article CAS PubMed Google Scholar
Polloni L, Muraro A, Bonaguro R, Toniolo A, Ballin A, Guarnaccia A, et al. Psychological needs and support among patients and families undergoing food oral immunotherapy. Clin Transl Allergy. 2022;12(2): e12078.
Article PubMed PubMed Central Google Scholar
Kaman K, Dhodapkar M, Shabanova V, McCollum S, Factor J, Leeds S. Validated anxiety assessments among pediatric patients with peanut allergy on oral immunotherapy. Ann Allergy Asthma Immunol. 2023;130(5):657–63.
Article CAS PubMed Google Scholar
Knibb RC, Herbert LJ, Jones CJ, Protudjer JLP, Screti C, Roleston C, et al. Global availability and uptake of psychological services for adults, caregivers and children with food allergy. Allergy. 2024. https://doi.org/10.1111/all.16204.
留言 (0)